<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786641</url>
  </required_header>
  <id_info>
    <org_study_id>2016-FXY-012-Dept. of RT</org_study_id>
    <nct_id>NCT02786641</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the efficiency and toxicities of induction chemotherapy of
      docetaxel, cisplatin and xeloda in nomogram-predicted high risk locoregionally advanced
      nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients receive intensity-modulated radiotherapy (IMRT) with a total dose of 68
      Gy or higher in 33 fractions to the primary tumor. Nomogram-predicted low risk patients
      (Group A) receive concurrent chemotherapy, while nomogram-predicted high risk patients are
      randomized to receive concurrent chemotherapy (Group B) or induction chemotherapy followed by
      concurrent chemotherapy (Group C). Induction chemotherapy consists of docetaxel 65 mg/m², D1,
      cisplatin 75 mg/m², D1 and Xeloda 2000mg/m², D1-14 every 3 weeks for 3 cycles. Concurrent
      chemotherapy consists of cisplatin 100 mg/m², D1 every 3 weeks for 3 cycles.The primary
      endpoint is failure-free survival (FFS). Secondary end points include overall survival (OS),
      locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and the
      incidence of grade 3 or higher acute toxicities. All efficacy analyses are conducted in the
      intention-to-treat population, and the safety population include only patients who receive
      their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FFS</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">235</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low risk NPC treated with concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high risk NPC treated with concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 65mg/m2 in induction chemotherapy</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 1</intervention_name>
    <description>Cisplatin 75mg/m2 in induction chemotherapy</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xeloda</intervention_name>
    <description>Xeloda 2000mg/m2 D1-14 in induction chemotherapy</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IMRT for all patients</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 2</intervention_name>
    <description>Cisplatin 100mg/m2 in concurrent chemotherapy</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly histologically confirmed non-keratinizing (WHO 1991) nasopharyngeal carcinoma.

          -  Tumor staged as III-IVb (the 2010 UICC/AJCC staging system).

          -  Karnofsky scale (KPS) ≥ 70.

          -  Adequate marrow: leucocyte count ≥ 4×10E9/L, hemoglobin ≥ 110g/L and platelet count ≥
             100×10E9/L.

          -  Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase
             (AST) and bilirubin ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline
             phosphatase (ALP) ≤ 2.5×ULN.

          -  Adequate renal function: creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5×ULN.

          -  Patients must give written informed consent.

        Exclusion Criteria:

          -  Prior malignancy, except adequately treated basal cell or squamous cell skin cancer,
             in situ cervical cancer.

          -  Pregnancy or lactation (consider pregnancy test in women of child-bearing age and
             emphasize effective contraception during the treatment period).

          -  History of previous radiotherapy (except for non-melanomatous skin cancers outside
             intended radiotherapy volume).

          -  Prior radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or
             nodes.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt;
             1.5×ULN), and emotional disturbance.

          -  Deficient in dihydropyrimidine dehydrogenase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fang-Yun Xie</last_name>
    <phone>+8602087342618</phone>
    <email>xiefy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009 Jan 10;27(2):242-9. doi: 10.1200/JCO.2008.18.1545. Epub 2008 Dec 8.</citation>
    <PMID>19064973</PMID>
  </reference>
  <reference>
    <citation>Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015 Apr 15;121(8):1328-38. doi: 10.1002/cncr.29208. Epub 2014 Dec 19.</citation>
    <PMID>25529384</PMID>
  </reference>
  <reference>
    <citation>Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, Mai HQ, Zeng MS. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst. 2015 Oct 14;108(1). pii: djv291. doi: 10.1093/jnci/djv291. Print 2016 Jan.</citation>
    <PMID>26467665</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fang-Yun Xie</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>nasopharyngeal carcinoma</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>docetaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>xeloda</keyword>
  <keyword>nomogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

